Cutaneous side effects during therapy with Erlotinib: Case report-Reference-Cited by-同舟云学术

Cutaneous side effects during therapy with Erlotinib: Case report

Published:2021 Issue:4 Volume:52 Page:317-320
ISSN:2490-3329
Container-title:Scripta Medica
language:en
Short-container-title:Scripta Medica

Author:

Jovičić Sanja,Gajanin Vesna,Umičević-Šipka Sanja

Abstract

Erlotinib is an antineoplastic drug used in the treatment of non-small cell lung cancer and pancreatic cancer. It is a potent, selective inhibitor of tyrosine kinase, a receptor for epidermal growth factor receptor (EGFR). Cutaneous side effects such as acneiform eruption, xerosis, telangiectasia, hair and nail changes are common. A case of a 70-year-old patient who developed unusual cutaneous side effects after 6 years of treatment with erlotinib was presented.

Publisher

Centre for Evaluation in Education and Science (CEON/CEES)

Link

https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2021/2490-33292104317J.pdf

Reference12 articles.

1. Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem 2020;20(10):815-34.;

2. Chen KL, Lin CC, Cho YT, Yang CW, Sheen YS, Tsai HE, et al. Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer. JAMA Dermatol 2016;152(3):340-2.;

3. Julian I, Iwamoto T. Investigation of biomarkers and handling strategy of erlotinib-induced skin rash in rats. Biol Pharm Bull 2021;44(8):1050-9.;

4. Carlesimo M, Pigliacelli F, D'Arino A, Caro G, Fortuna MC, Rossi A. Dermatologic management of oncotherapy side effects: a proposed algorithm. J Cosmet Dermatol 2021;20(2):429-36.;

5. Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol 2013;69(3):463-72.;